Concomitantly, cells treated with both nobiletin and IGF1 showed higher tumor viability than cells treated with nobiletin alone, implying that activating AKT could reverse the antitumor effects of nobiletin, and confirmed that nobiletin could indeed inhibit tumor growth via the AKT pathway. This evidence concerns the gene IGF1 and neoplasm.